KTKensuke Takaoka

Kensuke Takaoka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kensuke Takaoka has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations

    by Kensuke Takaoka, Sarah Mott, Ratdanai Yodsuwan, Sakditad Saowapa, Manasawee Tanariyakul, Chalothorn Wannaphut, Kittika Poonsombudlert

    Somatic mutations in the MAPK signaling pathway are frequently identified at AML diagnosis; however, their impact on treatment resistance and long‐term survival remains unclear. We conducted a retrospective study of patients with newly diagnosed MAPK‐mutated AML seen at the University of Iowa Health Care. The endpoints were overall survival (OS), composite complete remission (CRc) following induction therapy, and relapse‐free survival (RFS). Logistic and Cox regression models were used. Seventy‐four patients were included and 62 were induction eligible. Of the 62 patients receiving treatment, intensive induction was administered in 52.7%. The estimated 5‐year OS was 28.9%. On multivariable analysis, European LeukemiaNet 2022 adverse risk (hazard ratio [HR]: 3.56, 95% confident interval [CI]: 1.52–8.32) and KRAS mutation (HR: 2.14, 95% CI: 1.10–4.17) conferred inferior OS. Abnormal karyotype (odds ratio [OR]: 0.25, 95% CI: 0.07–0.89) and increasing age (OR: 0.97, 95% CI: 0.94–0.99) were associated with decreased odds of achieving a CRc. The median RFS after achieving a CRc was 13.3 months. We found that KRAS mutation conferred an inferior effect on OS and RFS but not CRc. These findings suggest that KRAS mutations may confer adverse prognostic significance and warrant validation in larger, multicenter cohorts.

  • Epidemiological survey of potential familial myelodysplastic syndromes/acute myeloid leukemia in Hawaii

    by Kensuke Takaoka, Manasawee Tanariyakul, Akihiro Miyashita, Yoshito Nishimura, Dominic Chow, Kenneth Sumida

    The epidemiology and clinical characteristics of familial myelodysplastic syndromes/acute myeloid leukemia (MDS/AML) remain poorly understood, particularly among Native Hawaiians and other Pacific Islanders (NHOPI). To investigate the real-world evidence in this area, we conducted a retrospective study at the Queen’s Medical Center, Hawaii's largest tertiary referral hospital. This study is based solely on self-reported family histories and interviews, without germline genetic validation. Among 1686 MDS/AML patients who presented between January 2012 and July 2023, 12 (0.71%) had familial MDS/AML and 25 (1.48%) had a family history of unspecified leukemia. While no NHOPI were identified among patients with familial MDS/AML, 20% of patients with a family history of unspecified leukemia were NHOPI. The median age at diagnosis of familial MDS/AML was 70 years, and 50% of familial MDS patients had MDS with low blasts based on the WHO 2022 classification. The median overall survival (OS) time and 5-year OS rate for familial MDS were 12.7 years and 75.0%, respectively. In contrast, familial AML had a median OS time of 0.85 years and a 3-year OS rate of 33.3%. Our study provides new insights into familial MDS/AML in Hawaii’s multiethnic population.

  • A comparative analysis of mechanical power and Its components in pressure-controlled ventilation mode and AVM-2 mode

    by Kensuke Takaoka, Shane Toma, Philip Lee, Ehab Daoud

    Background Mechanical ventilation is a critical therapeutic intervention in the management of patients with respiratory failure. Understanding the implications of different ventilation modes is essential in preventing ventilator-induced lung injuries (VILI). Recently, mechanical power has emerged as a critical element in the development of VILI and mortality. Previous bench work studies have suggested that new optimal (adaptive) modes, such as Adaptive Ventilation Mode 2 (AVM-2), can reduce the mechanical power in turn might reduce the rates of VILI. This study aims to compare the conventional Pressure-Controlled Ventilation (PCV) mode with an emerging design of Adaptive Ventilation Mode-2 (AVM-2), to measure the differences in mechanical power, alongside it’s components of PEEP, Tidal, Elastic, Resistive, Inspiratory, Total work, tidal volume, driving pressure and Power Compliance Index. Methods Between January 2023 and June of 2023, we conducted a prospective crossover study on twenty-two subjects admitted to our ICU within the first day after initiation of mechanical ventilation. Subjects were initially started on PCV settings chosen by the primary treatment team, then switched to AVM-2 with comparable minute ventilation. Mechanical power and its work components (tidal, resistive, PEEP, elastic, inspiratory, total), tidal volume, driving pressure, respiratory rate, and positive end-expiratory pressure, were recorded for each patient every 15 min for the duration of 2 consecutive hours on each mode. Statistical analysis, including paired t-tests were performed to assess the significance of differences between the two ventilation modes. The data is provided in means and 土 SD. Results There were significant differences between PCV and AVM-2 in mechanical power (J/min): 21.62 土 7.61 vs 14.21 土 6.41 (P < 0.001), PEEP work (J): 4.83 土 2.71 vs 4.11 土 2.51 (P < 0.001), Tidal work (J): 3.83 土 1.51 vs 2.21 土 0.89 (P < 0.001), Elastic work (J): 8.62 土 3.13 vs 6.32 土 3.21 (P < 0.001), Resistive work (J): 3.23 土 1.61 vs 1.81 土 1.31 (P 0.013), Inspiratory work (J): 6.95 土 2.58 vs 4.05 土 2.01 (P < 0.001), Total work (J): 11.81 土 3.81 vs 8.11 土 4.23 (P < 0.001). There were significant differences between PCV and AVM-2 in tidal volume (ml): 511 土 8.22 vs 413 土 10.21 (P < 0.001), tidal volume / IBW 7.38 土 1.74 vs 6.49 土 1.72 (P 0.004), driving pressure (cmH2O): 24.45 土 6.29 vs 20.11 土 6.59 (P 0.012), minute ventilation (L/min): 8.96 土 1.34 vs 7.42 土 1.41 (P < 0.001). The respiratory rate (bpm) was not significantly different between PCV and AVM-2 19.61 土 4.32 vs 18.32 土 1.43 (P 0.176). There were no significant differences between PCV and AVM-2 in static compliance (ml/cmH2O) 20.24 土 5.16 vs 22.72 土 6.79 (P 0.346), PaCO2 (mmHg) 44.94 土 9.62 vs 44.13 土 10.11 (P 0.825), and PaO2:FiO2 243.54 土 109.85 vs 274.21 土 125.13 (P 0.343), but significantly higher power compliance index in PCV vs AVM-2: 1.11 土 0.41 vs 0.71 土 0.33 (P < 0.001). Conclusion This study demonstrates that the choice of mechanical ventilation mode, whether PCV or AVM-2, significantly impacts mechanical power and its constituent variables. AVM-2 mode was associated with reduced mechanical power, and its’ components alongside the driving pressure, and tidal volumes, indicating its potential superiority in terms of lung-protective ventilation strategies. Clinicians should consider these findings when selecting the most appropriate ventilation mode to minimize the risk of ventilator-associated complications and improve patient outcomes. Further research is warranted to explore the clinical implications of these findings and to refine best practices in mechanical ventilation. Key words: Mechanical power, Work, PCV, AVM-2, VILI


  • Open Access

    Accidental ingestion of a long dental crown

    by Kensuke Takaoka, Chikashi Minemura, Hiromi Baba, Hidehiko Housyaku

    It is recommended that a sharp‐pointed object, such as a dental crown, in the proximal duodenum be retrieved endoscopically if this can be accomplished safely.

  • Mechanisms of pain in sickle cell disease

    by Kensuke Takaoka, Asha Caroline Cyril, Sandhya Jinesh, Rajan Radhakrishnan

    Objectives: The hallmark of sickle cell disease (SCD) is acute and chronic pain, and the pain dominates the clinical characteristics of SCD patients. Although pharmacological treatments of SCD targeting the disease mechanisms have been improved, many SCD patients suffer from pain. To overcome the pain of the disease, there have been renewed requirements to understand the novel molecular mechanisms of the pain in SCD. Methods: We concisely summarized the molecular mechanisms of SCD-related acute and chronic pain, focusing on potential drug targets to treat pain. Results: Acute pain of SCD is caused by vaso-occulusive crisis (VOC), impaired oxygen supply or infarction-reperfusion tissue injuries. In VOC, inflammatory cytokines include tryptase activate nociceptors and transient receptor potential vanilloid type 1. In tissue injury, the secondary inflammatory response is triggered and causes further tissue injuries. Tissue injury generates cytokines and pain mediators including bradykinin, and they activate nociceptive afferent nerves and trigger pain. The main causes of chronic pain are from extended hyperalgesia after a VOC and central sensitization. Neuropathic pain could be due to central or peripheral nerve injury, and protein kinase C might be associated with the pain. In central sensitization, neuroplasticity in the brain and the activation of glial cells may be related with the pain. Discussion: In this review, we summarized the molecular mechanisms of SCD-related acute and chronic pain. The novel treatments targeting the disease mechanisms would interrupt complications of SCD and reduce the pain of the SCD patients.


  • Open Access

    The First Case of Concomitant Mycobacterium genavense lymphadenitis and EBV-positive lymphoproliferative disorder

    by Yusuke Ito, Kensuke Takaoka, Kazuhiro Toyama, Yoshitaka Wakabayashi, Aya Shinozaki-Ushiku, Aiko Okazaki, Kinuyo Chikamatsu, Satoshi Mitarai, Tetsuo Ushiku, Mineo Kurokawa

    This is the first case of concurrent Mycobacterium genavense lymphadenitis and Epstein-Barr virus (EBV)-positive lymphoproliferative disorder (LPD) in the same lymph node with no immunocompromised history. M. genavense infection is a rare opportunistic infection mainly for human immunodeficiency virus (HIV)-infected patients. Although no immunodeficiency was detected in our patient, our case indicates that the immunodeficiency in the background of EBV latency type III and the immunosuppression by malignant lymphoma itself might induce the M. genavense lymphadenitis. This case highly alerts clinicians the immunosuppressive state of EBV-positive LPD with latency type III even if any serological immunodeficient factors are not detected.


  • Incidence rate and risk factors for giardiasis and strongyloidiasis in returning UK travellers

    by Kensuke Takaoka, Yannis Gourtsoyannis, John D. Hart, Margaret Armstrong, Amanda Daniel, Emma Mewse, Diana Phillips, Robin L. Bailey

    Background: Few studies have investigated incidence rate and risk factors for giardiasis and strongyloidiasis in returning UK travellers. The clinical presentations of these two diseases are often similar and difficult to distinguish. This study was conducted to investigate the incidence rate and the risk factors for symptomatic giardiasis and strongyloidiasis in returned tropical travellers. Methods: We retrospectively analysed 3306 consecutive attendances presenting to the emergency clinic at the Hospital for Tropical Diseases in London, the UK from September 2008 to May 2010. Odds ratios between the diagnoses and patient variables were analysed by logistic regression. Results: Giardiasis was diagnosed in 92/3306 cases (2.8%, proportionate morbidity), and the incidence rate per 1000 person-months was 12.5. Multivariate analysis with logistic regression revealed that Caucasian ethnicity (adjusted odds ratio (aOR): 2.37, 95% confidence interval (CI): 1.12–5.03, P value = 0.025), travel length ≥32 days (aOR: 2.63, 95%CI: 1.43–4.83, P = 0.002), travelling to South or South East Asia (aOR: 4.90, 95%CI: 2.03–11.8, P < 0.001, aOR: 3.36, 95%CI: 1.43–7.93, P = 0.006), afebrile presentation (aOR: 2.14, 95%CI: 1.14–4.03, P = 0.018), and presenting with gastro-intestinal symptoms (aOR: 14.6, 95%CI: 6.08–35.0, P < 0.001) were all associated with giardiasis. In contrast, strongyloidiasis was found only in 0.94% (proportionate morbidity) of the cases (31/3306), and the incidence rate per 1000 person-months was 3.1. Multivariate analysis revealed that male sex (aOR: 3.05, 95%CI: 1.36–6.85, P = 0.007), and non-Caucasian ethnicity (aOR: 2.69, 95%CI: 1.32–5.49, P = 0.007) were associated with strongyloidiasis. Conclusions: The incidence rate and risk factors for both infectious diseases were identified. The results of this study might guide clinicians to make more accurate and timely diagnoses in returned tropical travellers.